GENE ONLINE|News &
Opinion
Blog

Depression
ChatGPT’s Impact on Depression Management: A Game Changer in Mental Health
2023-10-25
Abbott’s Looks to Treat Depression With Breakthrough Device Status
2022-07-13
Refining Psychedelics into Medicine – An Interview with Doug Drysdale, CEO of Cybin
2022-04-19
The Renaissance of Psychedelics Research: An Interview with the CEO of MindMed, Rob Barrow
2022-04-12
Marijuana for Medical Use Increases the Risk of Cannabis Use Disorder
2022-03-25
History on Depression Therapy: the Past and the Psychedelic Future
2022-03-21
From Forbidden Drugs to Psychotropic Cures: A “Psychedelic Boom” Breaks New Ground in Treating Mental Illnesses
2022-03-08
Abbvie Acquires Neuroscience Company Syndesi for $1 Billion
2022-03-02
Mental Healthcare Startup Cerebral Valued at $4.8 Billion after $300 Million Softbank-led Series C
2021-12-10
Biogen and Sage Therapeutics Ink Deal for Treating Depression
2020-11-29
VistaGen’s Antidepressant Nasal Spray Succeeds Phase 2a Trial
2020-02-22
SECUADO – The Hope to Enhance Schizophrenia Patients’ Quality of Life
2019-11-14
Weekly in Asia|SEP
2019-09-27
FDA Approves New Drug for Specific Treatment of Postpartum Depression
2019-03-21
Top 3 Announcements at the J.P. Morgan Healthcare Conference 2019
2019-01-13
LATEST
Breakthrough Stem Cell Treatment Shows Promise in Reversing Liver Disease
2023-12-08
2023 Taiwan Healthcare Expo: Showcasing Innovative Advances in Biomedical Technology
2023-12-07
Absci Accelerates Breakthroughs in AI-Designed Drugs with AstraZeneca and Almirall Collaborations
2023-12-06
Saving Lives Through Communication, Heroic Faith Medical Science Showcasing Novel AI Auscultation Tool for Procedural Sedation Patients in PGA 77
2023-12-05
AbbVie Invests $10.1 Billion in ImmunoGen, Targeting the Ovarian Cancer Landscape
2023-12-05
PRISM BioLab and Eli Lilly Join Forces in Revolutionary Drug Discovery Collaboration
2023-12-05
Novel Hydrogel Delivery System Could Reduce Daily Diabetes Injections to Three Times a Year
2023-12-04
EVENT
Scroll to Top